IBDEI1BW ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22583,1,4,0)
 ;;=4^Z82.62
 ;;^UTILITY(U,$J,358.3,22583,2)
 ;;=^5063372
 ;;^UTILITY(U,$J,358.3,22584,0)
 ;;=Z83.71^^87^982^25
 ;;^UTILITY(U,$J,358.3,22584,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22584,1,3,0)
 ;;=3^Family Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,22584,1,4,0)
 ;;=4^Z83.71
 ;;^UTILITY(U,$J,358.3,22584,2)
 ;;=^5063386
 ;;^UTILITY(U,$J,358.3,22585,0)
 ;;=Z84.81^^87^982^29
 ;;^UTILITY(U,$J,358.3,22585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22585,1,3,0)
 ;;=3^Family Hx of Genetic Disease
 ;;^UTILITY(U,$J,358.3,22585,1,4,0)
 ;;=4^Z84.81
 ;;^UTILITY(U,$J,358.3,22585,2)
 ;;=^5063392
 ;;^UTILITY(U,$J,358.3,22586,0)
 ;;=Z86.010^^87^982^76
 ;;^UTILITY(U,$J,358.3,22586,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22586,1,3,0)
 ;;=3^Personal Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,22586,1,4,0)
 ;;=4^Z86.010
 ;;^UTILITY(U,$J,358.3,22586,2)
 ;;=^5063456
 ;;^UTILITY(U,$J,358.3,22587,0)
 ;;=Z86.14^^87^982^81
 ;;^UTILITY(U,$J,358.3,22587,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22587,1,3,0)
 ;;=3^Personal Hx of MRSA Infection
 ;;^UTILITY(U,$J,358.3,22587,1,4,0)
 ;;=4^Z86.14
 ;;^UTILITY(U,$J,358.3,22587,2)
 ;;=^5063464
 ;;^UTILITY(U,$J,358.3,22588,0)
 ;;=Z86.31^^87^982^77
 ;;^UTILITY(U,$J,358.3,22588,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22588,1,3,0)
 ;;=3^Personal Hx of Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,22588,1,4,0)
 ;;=4^Z86.31
 ;;^UTILITY(U,$J,358.3,22588,2)
 ;;=^5063467
 ;;^UTILITY(U,$J,358.3,22589,0)
 ;;=Z86.711^^87^982^107
 ;;^UTILITY(U,$J,358.3,22589,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22589,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,22589,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,22589,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,22590,0)
 ;;=Z86.72^^87^982^113
 ;;^UTILITY(U,$J,358.3,22590,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22590,1,3,0)
 ;;=3^Personal Hx of Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,22590,1,4,0)
 ;;=4^Z86.72
 ;;^UTILITY(U,$J,358.3,22590,2)
 ;;=^5063476
 ;;^UTILITY(U,$J,358.3,22591,0)
 ;;=Z87.310^^87^982^105
 ;;^UTILITY(U,$J,358.3,22591,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22591,1,3,0)
 ;;=3^Personal Hx of Osteoporosis Fx
 ;;^UTILITY(U,$J,358.3,22591,1,4,0)
 ;;=4^Z87.310
 ;;^UTILITY(U,$J,358.3,22591,2)
 ;;=^5063485
 ;;^UTILITY(U,$J,358.3,22592,0)
 ;;=Z87.442^^87^982^116
 ;;^UTILITY(U,$J,358.3,22592,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22592,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
 ;;^UTILITY(U,$J,358.3,22592,1,4,0)
 ;;=4^Z87.442
 ;;^UTILITY(U,$J,358.3,22592,2)
 ;;=^5063497
 ;;^UTILITY(U,$J,358.3,22593,0)
 ;;=Z87.81^^87^982^114
 ;;^UTILITY(U,$J,358.3,22593,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22593,1,3,0)
 ;;=3^Personal Hx of Traumatic Fx (Healed)
 ;;^UTILITY(U,$J,358.3,22593,1,4,0)
 ;;=4^Z87.81
 ;;^UTILITY(U,$J,358.3,22593,2)
 ;;=^5063513
 ;;^UTILITY(U,$J,358.3,22594,0)
 ;;=Z87.890^^87^982^109
 ;;^UTILITY(U,$J,358.3,22594,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22594,1,3,0)
 ;;=3^Personal Hx of Sex Reassignment
 ;;^UTILITY(U,$J,358.3,22594,1,4,0)
 ;;=4^Z87.890
 ;;^UTILITY(U,$J,358.3,22594,2)
 ;;=^5063517
 ;;^UTILITY(U,$J,358.3,22595,0)
 ;;=Z87.892^^87^982^74
 ;;^UTILITY(U,$J,358.3,22595,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22595,1,3,0)
 ;;=3^Personal Hx of Anaphylaxis
 ;;^UTILITY(U,$J,358.3,22595,1,4,0)
 ;;=4^Z87.892
 ;;^UTILITY(U,$J,358.3,22595,2)
 ;;=^5063519
 ;;^UTILITY(U,$J,358.3,22596,0)
 ;;=Z87.39^^87^982^102
 ;;^UTILITY(U,$J,358.3,22596,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22596,1,3,0)
 ;;=3^Personal Hx of Musculoskeletal/Connective Tissue Disease
